循环造血干/祖细胞水平可改善2型糖尿病长期肾脏结局的预测
该研究在意大利帕多瓦大学医院糖尿病中心纳入342例2型糖尿病患者,按循环造血干/祖细胞(HSPC)中位数分组,中位随访6.7年。高HSPC组复合肾脏结局发生率较低(校正HR 0.69 [95% CI 0.49, 0.97]),eGFR下降更慢;将HSPC信息加入慢性肾脏病预后联盟风险评分可显著改善对未来不良肾脏结局的区分度。
要点
- 高HSPC组复合肾脏结局风险较低,校正HR 0.69(95% CI 0.49, 0.97)。
- 高HSPC组eGFR下降更慢,白蛋白尿增加程度与低HSPC组相似。
- HSPC信息加入慢性肾脏病预后联盟风险评分可显著改善区分度。
核心结论
- HSPC水平可预测肾功能恶化,并在临床风险评分之外改善对2型糖尿病不良肾脏结局个体的识别。
研究设计与样本
- 研究纳入2004-2019年在帕多瓦大学医院糖尿病中心接受基线循环HSPC测定的2型糖尿病患者,按每毫升血中HSPC中位数分为两组,随访至2022年12月。
- 共分析342例参与者(67.8%为男性),平均年龄65.6岁;低HSPC组171例。
主要发现
- 低HSPC组较低HSPC组年龄更大,高血压、心力衰竭和肾病患病率更高(45.0% vs 33.9%;p=0.036),基线eGFR更低、白蛋白尿更高。
- 中位随访6.7年期间,高HSPC组较低HSPC组复合肾脏结局发生率更低(校正HR 0.69 [95% CI 0.49, 0.97]),eGFR下降更慢,白蛋白尿增加程度相似。
- 将HSPC信息加入慢性肾脏病预后联盟风险评分可显著改善对未来不良肾脏结局个体的区分度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM/HYPOTHESIS: We examined whether prediction of long-term kidney outcomes in individuals with type 2 diabetes can be improved by measuring circulating levels of haematopoietic stem/progenitor cells (HSPCs), which are reduced in diabetes and are associated with cardiovascular risk. METHODS: We included individuals with type 2 diabetes who had a baseline determination of circulating HSPCs in 2004-2019 at the diabetes centre of the University Hospital of Padua and divided them into two groups based on their median value per ml of blood. We collected updated data on eGFR and albuminuria up to December 2022. The primary endpoint was a composite of new-onset macroalbuminuria, sustained ≥40% eGFR decline, end-stage kidney disease or death from any cause. The analyses were adjusted for known predictors of kidney disease in the population with diabetes. RESULTS: We analysed 342 participants (67.8% men) with a mean age of 65.6 years. Those with low HSPC counts (n=171) were significantly older and had a greater prevalence of hypertension, heart failure and nephropathy (45.0% vs 33.9%; p=0.036), as evidenced by lower eGFR and higher albuminuria at baseline. During a median follow-up of 6.7 years, participants with high vs low HSPC counts had lower rates of the composite kidney outcome (adjusted HR 0.69 [95% CI 0.49, 0.97]), slower decline in eGFR and a similar increase in albuminuria. Adding the HSPC information to the risk score of the CKD Prognosis Consortium significantly improved discrimination of individuals with future adverse kidney outcomes. CONCLUSIONS/INTERPRETATION: HSPC levels predict worsening of kidney function and improve the identification of individuals with type 2 diabetes and adverse kidney outcomes over and beyond a clinical risk score.
引用
- Bonora BM, Morieri ML, Marassi M, et al. Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells. Diabetologia. 2023. PMID: 37712954. doi:10.1007/s00125-023-06002-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。